Home » Newsletters » BioWorld Science

BioWorld Science

May 21, 2003

View Archived Issues

Bayer claims new PPARdelta activators in recent patent

New IKK-2 inhibitors for cancer and inflammation reported by Pharmacia (Pfizer)

Novel CCR1 antagonists in early development at Pfizer

Pfizer presents new opioid antagonists for IBS, drug abuse, depression, etc.

Lilly researchers describe new antitumor agents with utility in colorectal cancer

New HCV NS3 protease inhibitors in Vertex research pipeline

Long-acting, locally effective antimuscarinic agents developed at Pharmacia (Pfizer)

HIV integrase inhibitors designed by Italian team

Ferring reveals novel DPP-IV inhibitors in recent patents

Arginine supplementation to be studied for sickle cell disease

Symlin dose-titration study results reported

Alferon N demonstrates positive outcome in animal model of SARS

Interim results from phase IV Keppra SKATE study

Isis and Ercole collaborate on antisense drugs that regulate alternative RNA splicing

CAT presents six-month interim update

Bexarotene reported effective in parapsoriasis

Clevudine safe and effective in chronic HBV infection

Antifungal activity of SPK-843 against clinical isolates

Promising results obtained for Bay-38-4766 in guinea pig CMV model

Anti-HBV dinucleotide with different mechanism of action from adefovir dipivoxil

European introduction of contraceptive transdermal matrix patch begins

Texas Biotechnology renamed

Iclaprim reported effective against several drug-resistant bacterial strains

EPI-2010 development discontinued

AtheroGenics reveals new asthma therapy at ATS 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...